|Bid||16.46 x 800|
|Ask||17.25 x 800|
|Day's Range||16.05 - 17.00|
|52 Week Range||4.76 - 24.30|
|Beta (5Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.50|
Ocular Therapeutix (NASDAQ: OCUL) recently reported fourth-quarter earnings with a loss of $85.6 million. While sales of Dextenza, Ocular's only approved therapeutic, were up an impressive 28% quarter over quarter, the drug's sales of $7 million are still a far cry from its potential peak sales of $600 million or more. In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the future of Ocular Therapeutix and how investors should be valuing the biotech.
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.78% and -4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided updates on its leading ophthalmology pipeline.